Press coverage about OpGen (NASDAQ:OPGN) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OpGen earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 44.1398176310107 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have effected Accern Sentiment Analysis’s rankings:
- OpGen Presents Data at ASM Microbe 2018 Demonstrating High Accuracy of Acuitas® for Predicting Antibiotic Resistance in Urine Specimens (finance.yahoo.com)
- Miragen Therapeutics (MGEN) & OpGen (OPGN) Financial Analysis (americanbankingnews.com)
- OpGen (OPGN) versus InVitae (NVTA) Head-To-Head Comparison (americanbankingnews.com)
- Should You Be Careful About Investing in Stock?: OpGen, Inc. (OPGN) (nysewired.com)
- What You Absolutely Can’t Miss: Jones Energy, Inc. (NYSE:JONE), OpGen, Inc. (NASDAQ:OPGN), JMP Group LLC … (thestreetpoint.com)
Shares of OPGN stock traded down $0.18 during trading hours on Thursday, reaching $2.12. The company’s stock had a trading volume of 6,961 shares, compared to its average volume of 496,053. The company has a market cap of $16.70 million, a PE ratio of -0.22 and a beta of 1.40. OpGen has a fifty-two week low of $1.62 and a fifty-two week high of $19.50. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.35 and a current ratio of 2.45.
OpGen (NASDAQ:OPGN) last issued its earnings results on Tuesday, May 8th. The medical research company reported ($0.75) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.84) by $0.09. The firm had revenue of $0.85 million for the quarter, compared to the consensus estimate of $0.74 million. OpGen had a negative return on equity of 437.11% and a negative net margin of 409.83%. equities analysts predict that OpGen will post -2.38 EPS for the current fiscal year.
A number of research firms have commented on OPGN. Zacks Investment Research lowered OpGen from a “hold” rating to a “sell” rating in a research note on Friday, June 1st. HC Wainwright set a $9.00 price objective on OpGen and gave the stock a “buy” rating in a research note on Friday, March 16th. Finally, ValuEngine raised OpGen from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.
OpGen Company Profile
OpGen, Inc, a precision medicine company, engages in developing molecular information products and services to combat infectious diseases in the healthcare industry worldwide. The company utilizes molecular diagnostics and bioinformatics to help combat infectious diseases. It also helps clinicians with information about life threatening infections, enhance patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.